Notwithstanding positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. These companies are https://jimguvw958582.losblogos.com/40705457/copyright-s-vyndamax-faces-is-dealing-with-pbm-hurdles-a-review-at-coverage-fights